TOWARDS NEW HUMAN BRUCELLOSIS VACCINE: SELECTING IMMUNIZATION MODALITY
Dina A Bugybayeva1, https://orcid.org/0000-0003-1891-2748,
Sholpan Zh Ryskeldinova1, https://orcid.org/0000-0002-6538-8486,
Zhailaubay K Kydyrbayev1, https://orcid.org/0000-0001-9247-6273,
Yerken M Kozhamkulov1, https://orcid.org/0000-0003-4105-2889,
Dulat A Inkarbekov1, https://orcid.org/0000-001-6274-5874,
Roman Y Shvecov1, https://orcid.org/0000-0002-3931-335X,
Kaissar K Tabynov2, https://orcid.org/0000-0001-5823-1280
1Research Institute for Biological Safety Problems, pgt. Gvardeyskiy, Republic of Kazakhstan,
2Kazakh National Agrarian University, Almaty c., Republic of Kazakhstan
There is no licensed, protective and safe vaccine against human brucellosis.
Objective. The main purpose of this work is to evaluate mucosal immunization route of vaccine candidate for human brucellosis in laboratory animals.
Material and methods. We used tetravalent vaccine formulations utilizing recombinant influenza A virus subtype H5N1 expressing Brucella proteins Omp 16, L7/L12 and Omp19 or Cu-Zn SOD with N-terminal 80 or 124 amino acids of the NS1 protein. Vaccine formulations administered to guinea pigs via mucosal sites including respiratory mucosa (nasal), conjunctiva and oral mucosa (sublingual). Animal body weight changes were recorded weekly. Blood samples were collected from guinea pigs of the control and experimental groups on days 0, 21 and 42 upon the prime and boost immunizations to detect antibodies against influenza A virus subtype H5N1 using hemagglutination-inhibition assay (HIA).
Results and discussion. The highest antibody response to influenza A virus subtype H5N1 in guinea pigs detected when vaccine formulations were administered at nasal route upon prime-boost immunization. Animal deaths and body weight loss were not observed over 42 days.
Conclusion. The data obtained indicate that intranasal immunization of guinea pigs showed a detectable accumulation of antibodies after prime-boost immunization.
Keywords: human brucellosis, mucosal vaccine, influenza viral vector.